Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma

International Journal of Molecular Sciences(2020)10.3390/ijms21010344Source: DataRank Database

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma is a research paper published in International Journal of Molecular Sciences (2020). On theSindex it has a DataRank of 0. It has been cited 33 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access33 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (68)IDs (PubMed, PMC)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Jacquelyn T. Saunders ORCID,Brent Holmes ORCID,Robert N. Nishimura,Alan Lichtenstein,Joseph Gera ORCID

Live enrichment

PubMed:31948038 PMC:PMC6981868

National Cancer Institute

Grant: R01CA214246

U.S. Department of Veterans Affairs

Grant: I01 BX002665

NCI NIH HHS

Grant: R01 CA217820

National Institutes of Health

Grant: 5R01CA214246-04

Regulation of c-myc translation by hnRNP A1: Role in multiple myeloma tumor responses

National Institutes of Health

Grant: 5R01CA217820-03

Co-targeting mTOR and YAP signaling in glioblastoma

goldLicense: cc-by

publisherhttps://www.mdpi.com/1422-0067/21/1/344/pdf?version=1578365491

repositoryhttps://doaj.org/article/2b6e47cfebdc4f6bb9e3cb2c7dd72784

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/6981868

repositoryhttp://dx.doi.org/10.3390/ijms21010344

Europe_PMChttps://europepmc.org/articles/PMC6981868

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Cell Line, TumorAnimalsHumansMiceMice, SCIDGlioblastomaRiluzoleAntineoplastic AgentsApoptosisCell ProliferationCell MovementProtein BiosynthesisDrug SynergismDrug Resistance, NeoplasmFemaleDrug RepositioningTOR Serine-Threonine KinasesMolecular Docking SimulationInternal Ribosome Entry SitesHeterogeneous Nuclear Ribonucleoprotein A1

Keywords

Drug resistanceGlioblastomaMtorRiluzoleHnrnp A1ItafHeterogeneous Nuclear Ribonucleoprotein A1ApoptosisMice, SCIDMiceCell MovementMedicinal and biomolecular chemistryCancerTumorTOR Serine-Threonine KinasesDrug SynergismMolecular Docking Simulation5.1 PharmaceuticalsFemale610Antineoplastic AgentsInternal Ribosome Entry SitesSCIDMicrobiologyArticleCell LineRare DiseasesCell Line, TumorGeneticsAnimalsHumansCell ProliferationChemical PhysicsNeurosciencesDrug RepositioningBrain DisordersBrain CancerOrphan DrugDrug Resistance, NeoplasmBiochemistry and cell biologyProtein BiosynthesisChemical SciencesNeoplasmOther Biological SciencesOther Chemical Sciences

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good health

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma

FAIR Checklist

Authors (6)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)